Tourmaline Bio Inc (NASDAQ:TRML)’s traded shares stood at 0.81 million during the last session, with the company’s beta value hitting 2.12. At the close of trading, the stock’s price was $17.15, to imply an increase of 1.60% or $0.27 in intraday trading. The TRML share’s 52-week high remains $30.00, putting it -74.93% down since that peak but still an impressive 30.79% since price per share fell to its 52-week low of $11.87. The company has a valuation of $440.51M, with an average of 0.44 million shares in intraday trading volume over the past 10 days and average of 283.96K shares over the past 3 months.
Tourmaline Bio Inc (NASDAQ:TRML) trade information
After registering a 1.60% upside in the last session, Tourmaline Bio Inc (TRML) has traded red over the past five days. The 5-day price performance for the stock is -8.78%, and 38.64% over 30 days. With these gigs, the year-to-date price performance is -15.43%. Short interest in Tourmaline Bio Inc (NASDAQ:TRML) saw shorts transact 3.42 million shares and set a 10.57 days time to cover.
The extremes give us $42 and $50 for target low and target high price respectively. As such, TRML has been trading -191.55% off suggested target high and -144.9% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 8.04% for the past 5-year period. While 2025 is set for a -21.68% return in earnings, projections for the next 5 years are at -19.64% annually.
TRML Dividends
Tourmaline Bio Inc has its next earnings report out on 2025-Mar-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Tourmaline Bio Inc (NASDAQ:TRML)’s Major holders
Tourmaline Bio Inc insiders hold 22.58% of total outstanding shares, with institutional holders owning 85.74% of the shares at 110.75% float percentage. In total, 85.74% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P.. As of 2024-06-30, the company held over 2.54 million shares (or 9.8699% of shares), all amounting to roughly $32.65 million.
The next major institution holding the largest number of shares is AVORO CAPITAL ADVISORS LLC with 2.22 million shares, or about 8.6387% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $28.58 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Tourmaline Bio Inc (TRML) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 647.38 shares. This is just over 2.52% of the total shares, with a market valuation of $11.1 million. Data from the same date shows that the other fund manager holds a little less at 620.32, or 2.42% of the shares, all valued at about 10.64 million.
